Sun Pharmaceutical Industries Limited has successfully concluded its postal ballot process, with shareholders approving three significant resolutions. The company confirmed the ratification of the Cost Auditor’s remuneration for FY 2025–26, the alteration of its Memorandum of Association, and the re-appointment of Dr. Pawan Goenka as an Independent Director for a second five-year term, effective 21 May 2026.
Postal Ballot Outcome
Following the conclusion of the voting period on 17 April 2026, Sun Pharmaceutical Industries Limited has officially declared the results of its recent postal ballot process. The resolutions, which were initially proposed in the notice dated 17 March 2026, have been duly passed by the shareholders with the required majority.
Key Corporate Decisions
The approved resolutions reflect important administrative and strategic updates for the company:
- Financial Governance: Shareholders have ratified the remuneration for the Cost Auditor regarding the 2025–26 fiscal year.
- Memorandum of Association: An alteration to Clause III(A), which governs the company’s Main Objects, has been formally approved.
- Leadership Continuity: Dr. Pawan Goenka has been re-appointed as an Independent Director. His new term of five years is set to commence on 21 May 2026.
Implementation and Compliance
These resolutions are deemed passed as of 17 April 2026. The company has fulfilled its requirements by filing the voting results in XBRL mode. Further details regarding the scrutineer’s findings are accessible to the public through the official company website.
Source: BSE
